MaxCyte (MXCT)

• Market cap: $476M
• 1 day: -1.74%
• 5 days: -0.22%
• 1 month: 8.41%
• 3 months: 25.98%
• 6 months: -6.04%
• Year to date: 8.67%
• 1 year: -11.39%
• 5 years: -73.47%
• 10 years: -73.47%
• Sector: Industrials
• Industry: Commercial Physical & Biological Research

About: MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.

Employees: 143

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

117% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 6

58% more repeat investments, than reductions

Existing positions increased: 49 | Existing positions reduced: 31

5% more funds holding

Funds holding: 114 [Q2] → 120 (+6) [Q3]

4.41% less ownership

Funds ownership: 70.01% [Q2] → 65.6% (-4.41%) [Q3]

7% less capital invested

Capital invested by funds: $288M [Q2] → $269M (-$18.8M) [Q3]

50% less funds holding in top 10

Funds holding in top 10: 4 [Q2] → 2 (-2) [Q3]

56% less call options, than puts

Call options by funds: $4K | Put options by funds: $9K